Neonates represent a unique population with distinct physiological characteristics. The application of Enhanced Recovery After Surgery (ERAS) principles in neonatal care remains in its early developmental stages. In 2024, the ERAS Society published evidence-based perioperative care recommendations tailored for neonates undergoing non-cardiac surgical procedures. These recommendations are intended to be implemented within the Neonatal Intensive Care Units (NICUs). This article provides an interpretation of the guideline, aiming to establish a reference framework for implementing ERAS in neonatal surgical care .
Heart transplantation is a key treatment option for patients with end-stage heart failure. However, post-transplant recipients often face complex rehabilitation challenges due to cardiac denervation, lifelong immunosuppressive therapy, and common complications such as hypertension, dyslipidemia, and post-transplant diabetes mellitus. This article aims to interpret the 2024 position paper jointly released by the European Society of Cardiology and the European Society for Organ Transplantation on post-transplant rehabilitation, and to systematically summarizes the core strategies proposed in rehabilitation management, including optimizing immunosuppressive therapy, individualized exercise prescriptions, lifestyle interventions, and psychosocial support.
Glycogen storage disease type Ib (GSD Ib) is a rare disorder of glycogen metabolism, often complicated by neutropenia/neutrophil dysfunction, leading to recurrent infections and the development of inflammatory bowel disease (IBD), which severely impacts patients’ quality of life. Empagliflozin, an SGLT2 inhibitor, has demonstrated the ability to restore neutrophil counts and function, thereby improving the immunodeficiency state in GSD Ib patients. This consensus aims to provide clinical practice recommendations for the use of empagliflozin in GSD Ib based on current evidence and expert experience. The purpose of this document is to outline these key points and offer guidance for the clinical application of empagliflozin in GSD Ib.
